There’s a lot to be optimistic about in the Conglomerates sector as 2 analysts just weighed in on Khiron Life Sciences (KHRNF) and Aphria (APHA) with bullish sentiments.
Khiron Life Sciences (KHRNF)
Canaccord Genuity analyst Kimberly Hedlin maintained a Buy rating on Khiron Life Sciences yesterday and set a price target of C$3.00. The company’s shares closed last Thursday at $0.44, close to its 52-week low of $0.22.
According to TipRanks.com, Hedlin is a 4-star analyst with an average return of 4.1% and a 42.9% success rate. Hedlin covers the Industrial Goods sector, focusing on stocks such as Decibel Cannabis Company, Delta 9 Cannabis, and MediPharm Labs.
Khiron Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.
See today’s analyst top recommended stocks >>
In a report released today, Matt Bottomley from Canaccord Genuity maintained a Buy rating on Aphria, with a price target of C$10.00. The company’s shares closed last Thursday at $3.59.
According to TipRanks.com, Bottomley is a 2-star analyst with an average return of -0.6% and a 43.0% success rate. Bottomley covers the Industrial Goods sector, focusing on stocks such as The Supreme Cannabis Company, Harvest Health & Recreation, and Green Thumb Industries.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aphria with a $5.34 average price target, implying a 46.3% upside from current levels. In a report issued on April 16, Eight Capital also upgraded the stock to Buy.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APHA: